Novel FabH inhibitors: a patent and article literature review (2000 – 2012)

Author： Luo Yin   Yang Yu-Shun   Fu Jie   Zhu Hai-Liang  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.11, 2012-11, pp. : 1325-1336

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel FabH inhibitors: an updated article literature review (July 2012 to June 2013)

By Song Heng   Ao Gui-Zhen   Li Huan-Qiu  

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 1, 2014-01 ,pp. : 19-27

Informa Healthcare

Access to resources Recommend Favorite

Advances in the Research of &bgr;-Ketoacyl-ACP Synthase III (FabH) Inhibitors

By  

Current Medicinal Chemistry, Vol. 19, Iss. 8, 2012-03 ,pp. : 1225-1237

Bentham Science Publishers

Access to resources Recommend Favorite

Glycogen phosphorylase inhibitors: a patent review (2008 - 2012)

By Gaboriaud-Kolar Nicolas   Skaltsounis Alexios-Leandros  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1017-1032

Informa Healthcare

Access to resources Recommend Favorite

Osteoclast differentiation inhibitors: a patent review (2008 – 2012)

By Kim Seong Hwan   Moon Seong-Hee  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 12, 2013-12 ,pp. : 1591-1610

Informa Healthcare

Access to resources Recommend Favorite

Antiobesity carbonic anhydrase inhibitors: a literature and patent review

By Scozzafava Andrea   Supuran Claudiu T   Carta Fabrizio  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 6, 2013-06 ,pp. : 725-735

Informa Healthcare

Access to resources Recommend Favorite